Hoth Therapeutics Files 8-K
Ticker: HOTH · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1711786
| Field | Detail |
|---|---|
| Company | Hoth Therapeutics, Inc. (HOTH) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: HOTH
TL;DR
HOTH filed an 8-K on 10/17/25, check for updates.
AI Summary
Hoth Therapeutics, Inc. filed an 8-K on October 17, 2025, reporting other events and financial statements. The filing does not contain specific financial figures or details about the nature of the events reported.
Why It Matters
This filing indicates that Hoth Therapeutics has made a regulatory submission to the SEC, which may contain updates on company events or financial status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not disclose specific material information that would immediately impact risk.
Key Players & Entities
- Hoth Therapeutics, Inc. (company) — Registrant
- October 17, 2025 (date) — Date of Report
- Nevada (jurisdiction) — State of Incorporation
- 1177 Avenue of the Americas (address) — Principal Executive Offices
- New York, NY 10036 (address) — Principal Executive Offices
- (646) 756-2997 (phone_number) — Registrant's telephone number
FAQ
What specific 'Other Events' are being reported by Hoth Therapeutics in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the 'Other Events' being reported, only that this item is being addressed.
When was this 8-K filing submitted to the SEC?
The filing was submitted on October 17, 2025.
What is Hoth Therapeutics, Inc.'s state of incorporation?
Hoth Therapeutics, Inc. is incorporated in Nevada.
What is the principal executive office address for Hoth Therapeutics, Inc.?
The principal executive office is located at 1177 Avenue of the Americas, 5th Floor, Suite 5066, New York, NY 10036.
Does this filing include specific financial statements or exhibits?
The filing indicates 'Financial Statements and Exhibits' as an item information, but the specific content of these is not detailed in the provided text.
Filing Stats: 525 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-10-17 16:15:34
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value HOTH The Nasdaq Stock Mar
Filing Documents
- ea0261354-8k_hoth.htm (8-K) — 25KB
- ea026135401ex99-1_hoth.htm (EX-99.1) — 27KB
- ex99-1_001.jpg (GRAPHIC) — 573KB
- ex99-1_002.jpg (GRAPHIC) — 998KB
- ex99-1_003.jpg (GRAPHIC) — 714KB
- ex99-1_004.jpg (GRAPHIC) — 248KB
- ex99-1_005.jpg (GRAPHIC) — 204KB
- ex99-1_006.jpg (GRAPHIC) — 135KB
- ex99-1_007.jpg (GRAPHIC) — 563KB
- ex99-1_008.jpg (GRAPHIC) — 209KB
- ex99-1_009.jpg (GRAPHIC) — 441KB
- ex99-1_010.jpg (GRAPHIC) — 609KB
- ex99-1_011.jpg (GRAPHIC) — 281KB
- ex99-1_012.jpg (GRAPHIC) — 685KB
- ex99-1_013.jpg (GRAPHIC) — 550KB
- ex99-1_014.jpg (GRAPHIC) — 213KB
- ex99-1_015.jpg (GRAPHIC) — 268KB
- ex99-1_016.jpg (GRAPHIC) — 539KB
- ex99-1_017.jpg (GRAPHIC) — 465KB
- ex99-1_018.jpg (GRAPHIC) — 133KB
- ex99-1_019.jpg (GRAPHIC) — 712KB
- ex99-1_020.jpg (GRAPHIC) — 204KB
- ex99-1_021.jpg (GRAPHIC) — 498KB
- ex99-1_022.jpg (GRAPHIC) — 206KB
- ex99-1_023.jpg (GRAPHIC) — 479KB
- ex99-1_024.jpg (GRAPHIC) — 157KB
- 0001213900-25-099969.txt ( ) — 14110KB
- hoth-20251017.xsd (EX-101.SCH) — 3KB
- hoth-20251017_lab.xml (EX-101.LAB) — 33KB
- hoth-20251017_pre.xml (EX-101.PRE) — 22KB
- ea0261354-8k_hoth_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. Hoth Therapeutics, Inc. (the "Company") has prepared presentation materials (the "Presentation Materials") that management intends to use from time to time on and after October 17, 2025, in presentations about the Company's operations and performance. The Presentation Materials are filed as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in the Presentation Materials is summary information that should be considered within the context of the Company's filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While the Company may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, the Company specifically disclaims any obligation to do so.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Presentation Materials 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 17, 2025 Hoth Therapeutics, Inc. /s/ Robb Knie Robb Knie Chief Executive Officer 2